Press Releases
TxCell announces publication of CATS1 study results for antigen-specific Treg therapy in Crohn¹s disease in Gastroenterology
TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, announces today...
Press Releases
Cytheris announces US Orphan Drug Designation for CYT107 for the treatment of Progressive Multifocal Leucoencephalopathy (PML)
Cytheris SA, a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases, announces today that the US Food and Drug Administration (FDA) has granted...
Press Releases
Domain Therapeutics enters into collaboration agreement with Ono in the field of GPCR-based drug discovery
Domain Therapeutics S.A. announced today that Domain Therapeutics and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a collaboration agreement focused on discovering small...
Press Releases
Adocia is extending its intellectual property to new formulations of monoclonal antibodies
Adocia , a biotech company specialized in the formulation of therapeutic proteins for the treatment of diabetes and chronic wounds, announces today that...
Clinical Trials
Idera completes patient enrollment in Phase 2 trial of IMO-3100
Idera Pharmaceuticals has concluded enrolling patients in double-blind, placebo-controlled Phase 2 trial assessing IMO-3100 in psoriasis patients. The study...
Press Releases
FDA Advisory Committee Recommends KYNAMRO™ for Homozygous Familial Hypercholesterolemia
Genzyme, a Sanofi company , and Isis Pharmaceuticals Inc. , announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S....
News
Antibiotic shows promise in treating extensively drug-resistant tuberculosis
When tested in patients hospitalized with extensively drug-resistant tuberculosis (XDR-TB) unresponsive to previous treatment, linezolid, an antibiotic used to treat severe bacterial infections,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read